Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement

• Prif Awduron: Ling Yu (Awdur), Jietao Lin (Awdur), Hanhan Li (Awdur), Lingling Sun (Awdur), Shubo Wang (Awdur), Yaoxu Chen (Awdur), Hanrui Chen (Awdur), Lizhu Lin (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Frontiers Media S.A., 2023-01-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Background: Cancer of unknown primary (CUP), which accounts for 3%-5% of new cancer cases every year, involves the presence of a type of histologically confirmed metastatic tumors whose primary site cannot be confirmed by conventional diagnostic methods. This difficulty in identifying the primary si...